- Details
- Neeraj Agarwal discusses FOXA1 alterations in prostate cancer with Emmanuel Antonarakis and Justin Hwang, exploring research that identifies FOXA1 mutations in 15% of prostate cancers, with higher prevalence in Asian (25%) and Black (20%) patients. Their Minnesota classification system reveals that different FOXA1 mutations can lead to opposing clinical outcomes: some variants enhance hormone sens...
|
- Details
- Zachary Klaassen speaks with Neeraj Agarwal about the Phase III randomized MEVPRO-1 study examining mevrometostat in combination with enzalutamide for mCRPC patients previously treated with abiraterone acetate. Dr. Agarwal explains that EZH2, a key component of the Polycomb Repressive Complex II, functions by adding methyl groups to histone proteins, leading to gene silencing. The trial randomizes...
|
- Details
- Andrea Miyahira interviews Xiaolin Zhu about a publication examining genomic and transcriptomic features of androgen receptor signaling inhibitor (ARSI) resistance in metastatic castration-resistant prostate cancer. Through analysis of paired metastatic biopsies taken before ARSI treatment and at disease progression, Dr. Zhu's team identifies three significant findings: a novel amplified enhancer...
|
- Details
- Daniel Childs discusses real-world outcomes of lutetium-PSMA-617 treatment in prostate cancer patients with liver metastases, based on Mayo Clinic registry data. Dr. Childs presents findings showing that patients with liver metastases experience shorter overall survival (approximately 8.3 months), complete fewer treatment cycles, and demonstrate lower PSA response rates compared to those without l...
|
- Details
- Mindy Graham discusses findings from her research on MYC-driven prostate cancer, recently published in Nature Communications. Using single-cell RNA sequencing and immunostaining, Dr. Graham's team reveals how MYC activation drives consistent changes in the tumor microenvironment across both human and mouse models of prostate cancer. The research demonstrates a surprising transition from an initial...
|
- Details
- Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann presents data showing that tumor-absorbed dose per injected activity decreases significantly across treatment cycles, with approximately 60% of cumulative absorbed dose occurring in the first two cycles. He explores differences i...
|
- Details
- Roni Haas joins Andrea Miyahira to discuss research on prostate cancer radioresistance, focusing on differences between conventional and hypofractionated radiation therapy approaches. The study reveals that conventional radiation treatment, involving multiple small doses over time, leads to a more aggressive radioresistant phenotype with greater mutations and driver gene dysregulation compared to...
|
- Details
- Felipe Eltit joins Andrea Miyahira to discuss his research on prostate cancer bone metastases, focusing on their structural characteristics and impact on bone health. His study investigates how these metastases, which occur in 90% of advanced prostate cancer patients, generate osteoblastic lesions that paradoxically lead to bone weakness and pain. Using high-resolution imaging techniques, includin...
|
- Details
- Zachary Klaassen and Luke Nordquist discuss TheranosticTrials.org, a comprehensive global website dedicated to theranostic education and clinical trial information. Dr. Nordquist explains how the platform has expanded from initially covering 150 trials across 12 cancer types to now featuring over 600 trials for 35 different cancers. The website serves as an educational resource for patients, physi...
|
- Details
- Sarah Amend discusses research on polyaneuploid cancer cells (PACCs) and their role in metastasis, published in Molecular Cancer Research. Dr. Amend explains how cancer cells under stress enter an adaptive endocycling state, increasing dramatically in size and genomic content without dividing. The discussion highlights their findings that cells in the PACC state are preferentially found in circula...
|
